GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878
REGD. OFFICE &FACTORY: 69/C GIDC INDUSTRIAL ESTATE,
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA
TEL: 0260-2430027 / 2400639
E-mail:hrm@gtbl.in.net

GTBL/BSE/NSE/2026-27/06

23rd April, 2026

Corporate Relationship Department
BSE Limited
Floor 25, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code – 506879

Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400051
Symbol: GUJTHEM

Dear Sir / Madam,

Sub: Press Release

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we submit herewith the Press Release of the Gujarat Themis Biosyn Limited ('the Company') with respect to asset purchase of Sanofi's Global Anti-TB and Anti-Infective Portfolio.

Further, a copy of the same is also available on the website of the Company, viz., www.gtbl.in

Kindly take the same on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,

For **Gujarat Themis Biosyn Limited**

VINEET GANESH GAWANKAR
Digitally signed by VINEET GANESH GAWANKAR
Date: 2026.04.23 23:33:31 +05'30'

Vineet Gawankar
Company Secretary and Compliance Officer

Press Release

Gujarat Themis Biosyn Ltd (GTBL) to acquire Sanofi's Global Anti-TB and Anti-Infective Portfolio; move toward Global Forward Integration

Mumbai, 23rd April, 2026: Gujarat Themis Biosyn Ltd., amongst the leading pharmaceutical companies with established capabilities in fermentation-based intermediates and active pharmaceutical ingredients (APIs), has announced the signing of an asset purchase agreement to acquire a portfolio of anti-tuberculosis (TB) and anti-infective brands from Sanofi, the French-holding company of the Sanofi group, headquartered in Paris. GTBL now looks forward to working with Sanofi to ensure a seamless transition and continuity of supply to patients globally.

The acquisition, which remains subject to obtaining antitrust and foreign direct investment approvals in applicable jurisdictions, would involve 13 established branded generic products with a strong presence across more than 55 countries in Europe, the Middle East and Africa. The concerned portfolio reported net sales of approximately EURO 62 million for the year ended 2025. The acquisition would include marketing authorizations, brands, regulatory dossiers, and inventory and associated commercial rights. The transaction does not involve the transfer of manufacturing facilities or employees, making it a capital-efficient and asset-light expansion for the company.

This move would represent a significant step in GTBL's strategy to strengthen its global pharmaceuticals platform and expand its presence in the anti-infective segment. The transaction would provide immediate access to regulated and semi-regulated markets, enabling GTBL to enhance its international footprint. It would also create a strong opportunity for forward integration, allowing the company to leverage its existing capabilities in fermentation-based intermediates and APIs to support the acquired finished dosage formulations portfolio and drive improved realizations across the value chain.

The portfolio currently operates at healthy gross margins, with potential for further improvement through backward integration and operational efficiencies. In addition, the acquisition would provide access to well-established brands with long-standing clinical relevance, offering a stable commercial base and scope for sustained growth through lifecycle management and geographic expansion.

The move would be aligned with overall global healthcare trends, particularly the burden of tuberculosis and bacterial infections worldwide. Global health initiatives around access to medicines continue to focus on eliminating tuberculosis by 2030, while there is increasing clinical and regulatory emphasis on the use of mature antibiotics to address antimicrobial resistance and multi-drug resistant infections.

Commenting on this development, Dr. Sachin Patel, Managing Director, GTBL, said,

"This acquisition would be a strategic milestone in GTBL's evolution toward a high-margin, fermentation-based pharmaceutical platform serving many patients in multiple regions. By leveraging our core competencies in fermentation-based product portfolio, we are transitioning toward a high-value mix that significantly improves our margin profile and operational efficiency. This move would serve as a gateway to extend our patient reach, explore and penetrate new regulated territories, establishing a truly global footprint for our specialized offerings. Controlling the process from fermentation to the final product minimizes supply chain risks and ensures long-term profitability improvement.

With multiple levers for value creation under our direct control, this acquisition will position GTBL to deliver consistent, long-term shareholder value while reinforcing our leadership in the fermentation space and growing the impact we have in global healthcare."

The company expects to unlock further value from the portfolio to be acquired through expansion into under-penetrated markets, development of new formulations and indications, and optimization of existing distribution networks. Additional opportunities include reactivation of marketing authorizations in select geographies and leveraging the portfolio's strong retail presence to drive consistent growth.

The consideration for the transaction would be EURO 158 million, payable in cash at closing and is expected to be funded by an optimal mix of debt and equity. The transaction is expected to be EPS accretive, supported by profitable branded generics sales, vertical integration and improved operating leverage.

The transaction is expected to close by the end of Q3FY27 (Quarter Ending 31st December 2026), subject to customary closing conditions, including antitrust and foreign direct investment approvals in applicable jurisdictions.

About Gujarat Themis Biosyn Limited

GTBL is an India-based pharmaceutical company engaged in the development, manufacturing and marketing of fermentation-based pharmaceutical intermediates and APIs across key therapeutic segments in India. The company specializes in fermentation-based product development and continues to expand its presence across the Indian and global markets with a focus on building an integrated and scalable pharmaceutical platform. https://www.gtbl.in/

For further information, please contact:

Gujarat Themis Biosyn Limited	**Investor Relations – Adfactors PR**
Mr. Krupesh Patel Chief Financial Officer krupesh.patel@themismedicare.com	Mr. Rahul Trivedi rahul.trivedi@adfactorspr.com Ms. Saloni Nagvekar saloni.nagvekar@adfactorspr.com